Baird analyst Brian Skorney downgraded Soleno Therapeutics (SLNO) to Neutral from Outperform with a price target of $53, down from $107, after Neurocrine (NBIX) announced a deal to acquire the company for $2.9B or $53 per share in cash.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics downgraded to Hold from Buy at Laidlaw
- Soleno Therapeutics rises 32.2%
- Midday Fly By: Neurocrine to acquire Soleno, Oracle hires new CFO
- Morning Movers: Soleno pops, Neurocrine dips after acquisition agreement
- Soleno Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald